Search

Displaying results 3821 - 3830 of 9887 in total
  1. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. … It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels.

  2. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34.

  3. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    A tripeptide with many roles in cells. … It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

    Mixtures: VitaHealth L-Glutathione PlusSynonyms: 5-L-Glutamyl-L-cysteinylglycine, gamma-L-Glutamyl-L-cysteinyl-glycine
  4. Drug

    Methenamine

    go.drugbank.com/drugs/DB06799
    ApprovedInvestigationalVet approved

    Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.

    Mixtures: Uro-L, Urin D/S
  5. Drug

    Chlortetracycline

    go.drugbank.com/drugs/DB09093
    ApprovedVet approvedWithdrawn

    The organism was named _Streptomyces aureofaciens_ due to its gold-hued color. … He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri.

  6. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements … Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.

  7. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050,L64051] It is administered as a single, one-time intravenous infusion. … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase

  8. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    Pemigatinib is a small molecule kinase inhibitor with antitumour activity. … [A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast

  9. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … [A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells

  10. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    can produce a broad adaptative and innate immune cell inhibitory activity. … All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]